Results 1 to 10 of about 46,143 (249)

A Case of Acute Kidney Injury During Eltrombopag Use Successfully Treated With Plasma Exchange in Addition to Antithrombotic Therapy [PDF]

open access: yesKidney Medicine
Eltrombopag (EPAG), a thrombopoietin receptor agonist, has emerged as a valuable option for the treatment of immune thrombocytopenic purpura. However, its use has raised concerns regarding thrombotic complications.
Noriko Ueno   +10 more
doaj   +2 more sources

Effect of blood groups on acquired and congenital thrombotic thrombocytopenic purpura and clinical correlation: Multi-center Turkish cohort study [PDF]

open access: yesHematology, Transfusion and Cell Therapy
Background: Thrombotic thrombocytopenic purpura (TTP) is a microangiopathic hemolytic anemia associated with ADAMTS-13 deficiency, a cleaving protease of von Willebrand factor (vWF).
Cevat İlteriş Kıkılı   +4 more
doaj   +2 more sources

Novel Mutation of Upshaw-Schulman Syndrome Associated with Coarctation of Aorta in Palestinian Child [PDF]

open access: yesĶazaķstannyṇ Klinikalyķ Medicinasy, 2020
Upshaw-Schulman syndrome is a rare inherited form of thrombotic thrombocytopenic purpura disease caused by deficiency of ADAMTS13 and reversible by fresh frozen plasma infusions.
Mahdi Zaid   +5 more
doaj   +1 more source

Case Report: Rabies Vaccine-Induced Thrombotic Thrombocytopenic Purpura in a Patient With Systemic Lupus Erythematosus

open access: yesFrontiers in Immunology, 2022
For patients with autoimmune diseases, vaccination is controversial. The use of vaccination in patients with autoimmune diseases is controversial. There are many reports of secondary thrombotic thrombocytopenic purpura cases after various vaccinations ...
Yanming Cui, Jianbo Wei, Xiang Peng
doaj   +1 more source

Concurrence of immune thrombocytopenic purpura and thrombotic thrombocytopenic purpura: a case report and review of the literature

open access: yesJournal of Medical Case Reports, 2023
Background Immune thrombocytopenic purpura and thrombotic thrombocytopenic purpura are both causes of thrombocytopenia. Recognizing thrombotic thrombocytopenic purpura is crucial for subsequent treatment and prognosis.
Hung-Chen Lin   +6 more
doaj   +1 more source

Coexistence of thrombotic thrombocytopenic purpura and immune thrombocytopenic purpura in an Asian woman: a case report

open access: yesJournal of International Medical Research, 2022
A 33-year-old Chinese woman with a history of immune thrombocytopenic purpura presented with heavy menstrual bleeding. She was found to have thrombocytopenia, plasma ADAMTS13 activity of 0%, and positivity for the plasma ADAMTS13 inhibitor.
Hangping Ge   +7 more
doaj   +1 more source

How I treat thrombotic thrombocytopenic purpura and atypical haemolytic uraemic syndrome [PDF]

open access: yes, 2014
Thrombotic thrombocytopenic purpura (TTP) and atypical haemolytic uraemic syndrome (aHUS) are acute, rare life-threatening thrombotic microangiopathies that require rapid diagnosis and treatment.
Goodship, T, Scully, M
core   +1 more source

Infection frequently triggers thrombotic microangiopathy in patients with preexisting risk factors : a single-institution experience [PDF]

open access: yes, 2010
Thrombotic microangiopathies are rare conditions characterized by microangiopathic hemolytic anemia, microthrombi, and multiorgan insult. The disorders, which include hemolytic uremic syndrome and thrombotic thrombocytopenic purpura, are often acute and ...
Catlow, Jamie   +4 more
core   +1 more source

Pathogenicity of anti-ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura. [PDF]

open access: yes, 2015
BACKGROUND: Acquired thrombotic thrombocytopenic purpura (TTP) is an autoimmune disease in which anti-ADAMTS13 autoantibodies cause severe enzyme deficiency.
Crawley, JT   +3 more
core   +2 more sources

Vincristine as an Adjunct to Therapeutic Plasma Exchange for Thrombotic Thrombocytopenic Purpura: A Single-Institution Experience

open access: yesBalkan Medical Journal, 2018
Background: Thrombotic thrombocytopenic purpura is a potentially life-threatening condition. Although the introduction of therapeutic plasma exchange has reduced mortality rates from over 90% to 10%-20%, approximately 40% of patients relapse, and ...
Seniz Öngören   +9 more
doaj   +1 more source

Home - About - Disclaimer - Privacy